You are currently on the new version of our website. Access the old version .

99 Results Found

  • Article
  • Open Access
2 Citations
1,786 Views
17 Pages

Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma

  • Fani Karagianni,
  • Christina Piperi,
  • Sara Valero-Diaz,
  • Camilla Amato,
  • Jose Pedro Vaque,
  • Berta Casar and
  • Evangelia Papadavid

17 September 2024

Angiogenesis plays a pivotal role in the growth and metastasis of tumors, including the development and progression of cutaneous lymphomas. The chick embryo CAM model has been utilized in various studies to assess the growth rate, angiogenic potentia...

  • Review
  • Open Access
4 Citations
6,430 Views
24 Pages

The Dual-Edged Sword: Risks and Benefits of JAK Inhibitors in Infections

  • Anders Jarneborn,
  • Pradeep Kumar Kopparapu and
  • Tao Jin

Janus kinase inhibitors (JAKis) represent a relatively new class of immunomodulatory drugs with potent effects on various cytokine signalling pathways. They have revolutionized the treatment landscape for autoimmune diseases such as rheumatoid arthri...

  • Article
  • Open Access
1 Citations
1,410 Views
13 Pages

Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects

  • Juan José Fernández-Cabero,
  • Carmen Lasa-Teja,
  • David San Segundo,
  • Alejandra Comins-Boo,
  • Juan Irure-Ventura,
  • David Walias Rivera,
  • Jose Luis Martín-Varillas,
  • Cristina Mata,
  • Montserrat Santos and
  • Marcos López-Hoyos
  • + 1 author

Recent concerns regarding the safety of Janus kinase inhibitors (JAKis) have prompted investigation into their impact on immune cell subsets in rheumatoid arthritis (RA) patients. This study aims to analyse alterations in immune cell populations indu...

  • Review
  • Open Access
31 Citations
10,007 Views
12 Pages

23 October 2023

Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment option, there remains significant concern regarding the risk o...

  • Article
  • Open Access
310 Views
12 Pages

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study

  • Carmen Lasa-Teja,
  • Juan José Fernández-Cabero,
  • Lara Sánchez-Bilbao,
  • Javier Loricera,
  • Iñigo González-Mazón,
  • Carmen Álvarez-Reguera,
  • Alba Herrero-Morant,
  • Alfonso Corrales-Martínez,
  • Virginia Portilla-González and
  • Ricardo Blanco
  • + 3 authors

30 December 2025

Background: Janus kinase inhibitors (JAKi) are approved for the treatment of rheumatoid arthritis (RA), aiming to achieve clinical remission. Composite scores such as Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP) are influen...

  • Article
  • Open Access
17 Citations
15,352 Views
42 Pages

4 December 2019

This paper offers an extension of Cauchy’s first law of motion to deformable bodies with internal resistance with application to earth pressures. In this respect, a unified continuum mechanics approach for deriving earth pressure coefficients f...

  • Article
  • Open Access
18 Citations
4,008 Views
21 Pages

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma

  • Fani Karagianni,
  • Christina Piperi,
  • Berta Casar,
  • Dalia de la Fuente-Vivas,
  • Rocío García-Gómez,
  • Kyriaki Lampadaki,
  • Vasiliki Pappa and
  • Evangelia Papadavid

20 February 2022

The combination of Resminostat (HDACi) and Ruxolitinib (JAKi) exerted cytotoxic effects and inhibited proliferation of CTCL cell lines (MyLa, SeAx) in previously published work. A xenograft tumor formation was produced by implanting the MyLa or SeAx...

  • Article
  • Open Access
6 Citations
2,671 Views
9 Pages

The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort

  • Denise Donzella,
  • Elisa Bellis,
  • Gloria Crepaldi,
  • Valeria Data,
  • Mariele Gatto,
  • Claudia Lomater,
  • Gaetano Liperoti,
  • Elena Marucco,
  • Marta Saracco and
  • Annamaria Iagnocco

14 June 2024

Background/Objectives: To date, the literature concerning real-world data on the retention rate and safety of Janus kinase inhibitors (JAKis) is limited. To retrospectively evaluate the overall drug retention rate (DRR) of different JAKis in a monoce...

  • Review
  • Open Access
3,753 Views
12 Pages

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review

  • Simone Lisa Böll,
  • Seyed Morteza Seyed Jafari,
  • Curdin Conrad and
  • Christoph Schlapbach

30 October 2025

Janus Kinase Inhibitors (JAKi) represent a novel class of drugs for the treatment of chronic inflammatory skin diseases. Topical JAKi (t-JAKi) offer targeted therapy at potentially reduced systemic side effects and improved long-term safety compared...

  • Article
  • Open Access
3 Citations
2,479 Views
12 Pages

Incidence Rates of Infections in Rheumatoid Arthritis Patients Treated with Janus Kinase or Interleukin-6 Inhibitors: Results of a Retrospective, Multicenter Cohort Study

  • Shuhei Yoshida,
  • Masayuki Miyata,
  • Eiji Suzuki,
  • Takashi Kanno,
  • Yuya Sumichika,
  • Kenji Saito,
  • Haruki Matsumoto,
  • Jumpei Temmoku,
  • Yuya Fujita and
  • Kiyoshi Migita
  • + 2 authors

20 May 2024

Objective: This study aimed to compare the incidence rates (IRs) of infections, including herpes zoster (HZ), in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) or interleukin-6 inhibitors (IL-6is). Methods: We retrosp...

  • Article
  • Open Access
19 Citations
6,611 Views
14 Pages

30 August 2021

Although Janus kinase inhibitors (JAKi) could reduce patient-reported pain in rheumatoid arthritis (RA), their mechanism remains unclear. Therefore, we examined lipid metabolites change in JAKi-treated patients and evaluate their association with pai...

  • Article
  • Open Access
6 Citations
1,959 Views
12 Pages

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis

  • Jumpei Temmoku,
  • Masayuki Miyata,
  • Eiji Suzuki,
  • Yuya Sumichika,
  • Kenji Saito,
  • Shuhei Yoshida,
  • Haruki Matsumoto,
  • Yuya Fujita,
  • Naoki Matsuoka and
  • Kiyoshi Migita
  • + 1 author

10 July 2023

Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical dat...

  • Review
  • Open Access
158 Citations
18,714 Views
40 Pages

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

  • Jacopo Angelini,
  • Rossella Talotta,
  • Rossana Roncato,
  • Giulia Fornasier,
  • Giorgia Barbiero,
  • Lisa Dal Cin,
  • Serena Brancati and
  • Francesco Scaglione

5 July 2020

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even repla...

  • Article
  • Open Access
16 Citations
5,393 Views
19 Pages

Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage

  • Annika Reddig,
  • Linda Voss,
  • Karina Guttek,
  • Dirk Roggenbuck,
  • Eugen Feist and
  • Dirk Reinhold

1 April 2021

Janus kinase inhibitors (JAKis) represent a new strategy in rheumatoid arthritis (RA) therapy. Still, data directly comparing different JAKis are rare. In the present in vitro study, we investigated the immunomodulatory potential of four JAKis (tofac...

  • Article
  • Open Access
4 Citations
3,129 Views
9 Pages

Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy

  • Marino Paroli,
  • Andrea Becciolini,
  • Alberto Lo Gullo,
  • Simone Parisi,
  • Elena Bravi,
  • Romina Andracco,
  • Valeria Nucera,
  • Francesca Ometto,
  • Federica Lumetti and
  • Alarico Ariani
  • + 48 authors

4 July 2024

Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration (...

  • Feature Paper
  • Review
  • Open Access
3 Citations
13,391 Views
19 Pages

Recent Advances in the Management of Acute Severe Ulcerative Colitis

  • Elaine Ong Ming San,
  • Kassem Sharif,
  • Konstantina Rosiou,
  • Michael Rennie and
  • Christian Philipp Selinger

6 December 2024

Acute severe ulcerative colitis is a medical emergency requiring inpatient treatment with intravenous steroids. Approximately one-third of patients do not respond to steroids sufficiently and require medical rescue therapy. Infliximab and cyclosporin...

  • Article
  • Open Access
7 Citations
3,988 Views
12 Pages

Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study

  • Caterina Baldi,
  • Simone Parisi,
  • Paolo Falsetti,
  • Jurgen Sota,
  • Maria Chiara Ditto,
  • Marco Capassoni,
  • Miriana D’alessandro,
  • Edoardo Conticini,
  • Francesca Nacci and
  • Serena Guiducci
  • + 3 authors

11 January 2024

Background: We provide the first prospective longitudinal multicenter experience on Upadacitinib efficacy and safety profile in Rheumatoid Arthritis (RA) in a real-life context, focusing on clinimetric and ultrasonographic (US) data. Methods: RA pati...

  • Article
  • Open Access
1,055 Views
10 Pages

A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes

  • Sara Lambiase,
  • Danilo Cavalloro,
  • Arnaldo Cioni,
  • Enrico Matteini,
  • Fabio Artosi,
  • Francesca Poscente,
  • Riccardo Belardi,
  • Alessandro Terrinoni,
  • Sergio Bernardini and
  • Laura Diluvio
  • + 1 author

18 November 2025

Background/Objectives: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently app...

  • Article
  • Open Access
4 Citations
3,577 Views
20 Pages

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes

  • Nina Yao,
  • Theresa Tretter,
  • Peter Kvacskay,
  • Wolfgang Merkt,
  • Norbert Blank,
  • Hanns-Martin Lorenz and
  • Lars-Oliver Tykocinski

Crosstalk between synovial fibroblasts (SF) and immune cells plays a central role in the development of rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi) have proven efficacy in the treatment of RA, although clinical responses are heterogeneo...

  • Brief Report
  • Open Access
1 Citations
3,042 Views
9 Pages

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

  • Elisabet Castañeda-Estévez,
  • Cristina Vergara-Dangond,
  • Martina Steiner,
  • Maria Beatriz Paredes-Romero,
  • Ana Esteban-Vázquez,
  • Tatiana Cobo-Ibañez,
  • Laura Trives-Folguera,
  • Maria Liz Romero-Bogado,
  • Isabel De La Cámara-Fernández and
  • Santiago Muñoz-Fernández
  • + 2 authors

27 December 2024

Background/Objectives: Janus kinase inhibitors (JAKi) have revolutionized the treatment of various inflammatory and immune disorders. Concerns about the potential increased risk of major adverse cardiovascular events (MACEs) associated with JAKi use...

  • Review
  • Open Access
1,246 Views
26 Pages

The Mechanisms of Resistance to JAK Inhibitors in Lymphoid Leukemias: A Scoping Review of Evidence from Preclinical Models and Case Reports

  • Daniel Martínez Anaya,
  • Marian Valladares Coyotecatl,
  • Maria del Pilar Navarrete Meneses,
  • Sergio Enríquez Flores and
  • Patricia Pérez-Vera

18 September 2025

The use of JAK inhibitors (JAKi) represents a promising therapeutic approach for patients with lymphoid leukemias (Lym-L). Clinical trials are ongoing to evaluate the safety and efficacy of JAK inhibitors. Over the last years, there have been reports...

  • Article
  • Open Access
4 Citations
3,119 Views
11 Pages

Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis

  • Irma Convertino,
  • Valentina Lorenzoni,
  • Rosa Gini,
  • Giuseppe Turchetti,
  • Elisabetta Fini,
  • Sabrina Giometto,
  • Claudia Bartolini,
  • Olga Paoletti,
  • Sara Ferraro and
  • Ersilia Lucenteforte
  • + 4 authors

21 March 2023

This study is aimed at describing tofacitinib and baricitinib users by characterizing their prescription and healthcare histories, drug and healthcare utilization patterns, and direct costs from a healthcare system perspective. This retrospective coh...

  • Article
  • Open Access
15 Citations
2,637 Views
11 Pages

The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy

  • Kristina Jevnikar,
  • Luka Lapajne,
  • Daniel Petrovič,
  • Andrej Meglič,
  • Mateja Logar,
  • Nataša Vidovič Valentinčič,
  • Mojca Globočnik Petrovič,
  • Ines Cilenšek and
  • Polona Jaki Mekjavić

21 June 2022

The proposed SARS-CoV-2-induced dysregulation of the renin-angiotensin-aldosterone (RAAS) system results in endothelial dysfunction and microvascular thrombosis. The retinal plexuses contain terminal vessels without anastomotic connections, making th...

  • Article
  • Open Access
7 Citations
6,087 Views
13 Pages

Synaptotagmin-13 Is a Neuroendocrine Marker in Brain, Intestine and Pancreas

  • Marta Tarquis-Medina,
  • Katharina Scheibner,
  • Ismael González-García,
  • Aimée Bastidas-Ponce,
  • Michael Sterr,
  • Jessica Jaki,
  • Silvia Schirge,
  • Cristina García-Cáceres,
  • Heiko Lickert and
  • Mostafa Bakhti

20 November 2021

Synaptotagmin-13 (Syt13) is an atypical member of the vesicle trafficking synaptotagmin protein family. The expression pattern and the biological function of this Ca2+-independent protein are not well resolved. Here, we have generated a novel Syt13-V...

  • Article
  • Open Access
1 Citations
1,404 Views
23 Pages

Microbiological and Sensory Quality of Artisanal Sour Cream

  • Darija Bendelja Ljoljić,
  • Melita Boroša,
  • Ivica Kos,
  • Luka Cvetnić,
  • Ivan Vnučec,
  • Nataša Hulak,
  • Biljana Radeljević and
  • Vesna Jaki Tkalec

24 July 2025

Following hygiene standards in milk production is essential for making high-quality sour cream, especially when using traditional methods that rely on raw milk. The aim of this study was to determine the physicochemical, microbiological, and sensory...

  • Article
  • Open Access
1,218 Views
24 Pages

Reading Assessment and Eye Movement Analysis in Bilateral Central Scotoma Due to Age-Related Macular Degeneration

  • Polona Zaletel Benda,
  • Grega Jakus,
  • Jaka Sodnik,
  • Nadica Miljković,
  • Ilija Tanasković,
  • Smilja Stokanović,
  • Andrej Meglič,
  • Nataša Vidovič Valentinčič and
  • Polona Jaki Mekjavić

This study investigates reading performances and eye movements in individuals with eccentric fixation due to age-related macular degeneration (AMD). Overall, 17 individuals with bilateral AMD (7 males; mean age 77.47 ± 5.96 years) and 17 controls (10...

  • Article
  • Open Access
12 Citations
4,767 Views
8 Pages

In Vitro Activities of Enantiopure and Racemic 1′-Acetoxychavicol Acetate against Clinical Isolates of Mycobacterium tuberculosis

  • Saradee Warit,
  • Kamolchanok Rukseree,
  • Therdsak Prammananan,
  • Poonpilas Hongmanee,
  • Pamaree Billamas,
  • Sarinya Jaitrong,
  • Angkana Chaiprasert,
  • Birgit U. Jaki,
  • Guido F. Pauli and
  • Prasit Palittapongarnpim

18 September 2017

In the process of evaluating the effect of several plant extracts against Mycobacterium tuberculosis using the Microplate Alamar Blue Assay (MABA), an extract of Thai herb Alpinia galanga rhizome and its major component, 1′-acetoxychavicol acetate (A...

  • Article
  • Open Access
17 Citations
4,907 Views
14 Pages

In the existing studies devoted to predicting bankruptcy, the authors of such models only used book measures. Considering the fact that the evolution of corporate measure efficiency (in addition to book measures) brought into existence and exposed th...

  • Article
  • Open Access
14 Citations
3,678 Views
19 Pages

There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials....

  • Article
  • Open Access
43 Citations
4,581 Views
12 Pages

A Two-Year Occurrence of Fusarium T-2 and HT-2 Toxin in Croatian Cereals Relative of the Regional Weather

  • Maja Kiš,
  • Ana Vulić,
  • Nina Kudumija,
  • Bojan Šarkanj,
  • Vesna Jaki Tkalec,
  • Krunoslav Aladić,
  • Mario Škrivanko,
  • Sanja Furmeg and
  • Jelka Pleadin

7 January 2021

To investigate into the T-2 and HT-2 toxin occurrence, 240 samples of unprocessed cereals (maize, wheat, barley, and oats) were sampled from different fields located in three Croatian regions during 2017–2018. In all samples, sum concentrations...

  • Article
  • Open Access
53 Citations
5,403 Views
16 Pages

Multi Locus Sequence Typing and spa Typing of Staphylococcus aureus Isolated from the Milk of Cows with Subclinical Mastitis in Croatia

  • Luka Cvetnić,
  • Marko Samardžija,
  • Sanja Duvnjak,
  • Boris Habrun,
  • Marija Cvetnić,
  • Vesna Jaki Tkalec,
  • Dražen Đuričić and
  • Miroslav Benić

Background: The bacterial species S. aureus is the most common causative agent of mastitis in cows in most countries with a dairy industry. The prevalence of infection caused by S. aureus ranges from 2% to more than 50%, and it causes 10–12% of all c...

  • Proceeding Paper
  • Open Access
2 Citations
1,226 Views
7 Pages

Transfer Learning-Based Anomaly Detection System for Autonomous Vehicle

  • Md. Humayun Kabir,
  • Mohammad Nadib Hasan,
  • Ahmad and
  • Hassan Jaki

15 November 2023

The advancements in technology have brought about significant changes in the automobile industry. A system that combines the control of a physical process with computing technology and communication networks is called a cyber–physical system (C...

  • Article
  • Open Access
1 Citations
2,605 Views
15 Pages

Face Recognition Characteristics in Patients with Age-Related Macular Degeneration Determined Using a Virtual Reality Headset with Eye Tracking

  • Nina Žugelj,
  • Lara Peterlin,
  • Urša Muznik,
  • Pia Klobučar,
  • Polona Jaki Mekjavić,
  • Nataša Vidović Valentinčić and
  • Ana Fakin

22 January 2024

Background and Objectives: Face recognition is one of the most serious disabilities of patients with age-related macular degeneration (AMD). Our purpose was to study face recognition using a novel method incorporating virtual reality (VR) and eye tra...

  • Article
  • Open Access
4 Citations
2,106 Views
13 Pages

16 May 2023

Our study evaluated visual function changes after subthreshold micropulse laser (SML) treatment in persistent central serous chorioretinopathy (CSC) and SML safety profile. We conducted a prospective study including 31 fovea-involving CSC patients. T...

  • Article
  • Open Access
5 Citations
5,985 Views
16 Pages

13 February 2023

In times of crisis, science communication needs to be accessible and convincing. In order to understand whether these two criteria apply to concrete science communication formats, it is not enough to merely study the communication product. Instead, t...

  • Article
  • Open Access
9 Citations
2,829 Views
11 Pages

The Comparison of Retinal Microvascular Findings in Acute COVID-19 and 1-Year after Hospital Discharge Assessed with Multimodal Imaging—A Prospective Longitudinal Cohort Study

  • Kristina Jevnikar,
  • Andrej Meglič,
  • Luka Lapajne,
  • Mateja Logar,
  • Nataša Vidovič Valentinčič,
  • Mojca Globočnik Petrovič and
  • Polona Jaki Mekjavić

17 February 2023

This study aimed to quantify possible long-term impairment of the retinal microcirculation and microvasculature by reassessing a cohort of patients with acute COVID-19 without other known comorbidities one year after their discharge from the hospital...

  • Article
  • Open Access
1 Citations
2,804 Views
16 Pages

13 January 2023

A study of the efficiency of the energy companies that are listed on the Polish capital market, which will be the object of the analysis in this paper, is focused on assessing the degree of accomplishment of their basic financial objectives, namely,...

  • Article
  • Open Access
5 Citations
3,465 Views
14 Pages

25 December 2021

Central serous chorioretinopathy (CSC) is a chorioretinal disease that usually affects the middle-aged population and is characterised by a thickened choroid, retinal pigment epithelium detachment, and subretinal fluid with a tendency towards spontan...

  • Article
  • Open Access
829 Views
18 Pages

Head and Eye Movements During Pedestrian Crossing in Patients with Visual Impairment: A Virtual Reality Eye Tracking Study

  • Mark Mervic,
  • Ema Grašič,
  • Polona Jaki Mekjavić,
  • Nataša Vidovič Valentinčič and
  • Ana Fakin

Real-world navigation depends on coordinated head–eye behaviour that standard tests of visual function miss. We investigated how visual impairment affects traffic navigation, whether behaviour differs by visual impairment type, and whether this funct...

  • Article
  • Open Access
3 Citations
3,387 Views
12 Pages

Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors

  • Andrea Cito,
  • Marco Fornaro,
  • Angela Carenza,
  • Maria Grazia Anelli,
  • Crescenzio Scioscia,
  • Florenzo Iannone and
  • Giuseppe Lopalco

29 July 2024

Objectives: This study aimed to evaluate the incidence of Herpes Zoster (HZ) in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi), and to predict potential risk factors for HZ development. Methods: We retrospectively...

  • Review
  • Open Access
7 Citations
5,838 Views
19 Pages

Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis

  • Benedetto Neri,
  • Roberto Mancone,
  • Mariasofia Fiorillo,
  • Sara Concetta Schiavone,
  • Stefano Migliozzi and
  • Livia Biancone

27 November 2024

Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive r...

  • Article
  • Open Access
1 Citations
1,842 Views
11 Pages

Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia

  • Jumpei Temmoku,
  • Masayuki Miyata,
  • Eiji Suzuki,
  • Yuya Sumichika,
  • Kenji Saito,
  • Shuhei Yoshida,
  • Haruki Matsumoto,
  • Yuya Fujita,
  • Naoki Matsuoka and
  • Kiyoshi Migita
  • + 2 authors

21 July 2023

Objectives: To determine whether drug-induced lymphocytopenia is associated with drug retention rates of JAKi (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. Methods: Patients with RA who were initiated with tofacitinib (n = 38) o...

  • Article
  • Open Access
27 Citations
4,763 Views
11 Pages

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study

  • Vincenzo Venerito,
  • Andreina Manfredi,
  • Antonio Carletto,
  • Stefano Gentileschi,
  • Fabiola Atzeni,
  • Serena Guiducci,
  • Marlea Lavista,
  • Laura La Corte,
  • Elisa Pedrollo and
  • Marco Sebastiani
  • + 4 authors

26 January 2023

Background: The aim of this multicenter retrospective study was to investigate the effectiveness and safety of the available JAK-inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD). Methods: We retrospecti...

  • Article
  • Open Access
8 Citations
3,670 Views
9 Pages

High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study

  • Beatriz Frade-Sosa,
  • Andrés Ponce,
  • Virginia Ruiz-Esquide,
  • Maria Jesús García-Yébenes,
  • Rosa Morlá,
  • Nuria Sapena,
  • Julio Ramirez,
  • Ana Belen Azuaga,
  • Juan Camilo Sarmiento and
  • Raimon Sanmarti
  • + 1 author

Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Metho...

  • Review
  • Open Access
2,983 Views
38 Pages

Medium and variable vessel vasculitides are a heterogeneous group of rare, immune-mediated vascular disorders that are associated with significant morbidity and mortality. The standard treatment approach involves glucocorticoids and immunosuppressive...

  • Communication
  • Open Access
40 Citations
6,322 Views
10 Pages

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

  • Vincenzo Venerito,
  • Pasquale Stefanizzi,
  • Luca Cantarini,
  • Marlea Lavista,
  • Maria Grazia Galeone,
  • Antonio Di Lorenzo,
  • Florenzo Iannone,
  • Silvio Tafuri and
  • Giuseppe Lopalco

Rheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those on biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in...

  • Article
  • Open Access
10 Citations
3,531 Views
11 Pages

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

  • Valentine Deprez,
  • Laure Le Monnier,
  • Jean-Marc Sobhy-Danial,
  • Franck Grados,
  • Isabelle Henry-Desailly,
  • Sarah Salomon-Goëb,
  • Thibault Rabin,
  • Sanja Ristic,
  • Mathurin Fumery and
  • Vincent Goëb

16 October 2020

Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricit...

  • Review
  • Open Access
26 Citations
7,143 Views
27 Pages

Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature

  • Andreea Roxana Furtunescu,
  • Simona Roxana Georgescu,
  • Mircea Tampa and
  • Clara Matei

Psoriasis is a highly prevalent dermatological disease associated with an increased systemic inflammatory response. In addition, joint involvement is also present in around 20% of patients. Therefore, treatment modalities used in this condition shoul...

  • Article
  • Open Access
2 Citations
1,583 Views
11 Pages

Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?

  • Marta Novella-Navarro,
  • Ana Van Den Rym,
  • Chary López-Pedrera,
  • Ana Martínez-Feito,
  • Beatriz Nieto-Carvalhal,
  • Keren Reche,
  • Clementina López-Medina,
  • Alejandro Escudero-Contreras,
  • Pilar Nozal and
  • Chamaida Plasencia-Rodríguez
  • + 4 authors

27 February 2025

Background: Obesity is a frequent comorbidity in rheumatoid arthritis (RA). This condition may lead these patients to have poorer disease control and a worse response to some of the available treatments. Objectives: We aim to analyze the role of body...

  • Perspective
  • Open Access
4 Citations
5,134 Views
14 Pages

Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management

  • Giovanni Paolino,
  • Mario Valenti,
  • Andrea Carugno,
  • Matteo Bianco,
  • Dario Didona,
  • Matteo Riccardo Di Nicola,
  • Pier Luigi Acutis,
  • Carmen Cantisani,
  • Vittoria Giulia Bianchi and
  • Santo Raffaele Mercuri
  • + 2 authors

1 January 2025

Background and Objectives: Janus kinase inhibitors (JAKi) have significantly advanced the treatment of various dermatological conditions by modulating the JAK-STAT signalling pathway. While these inhibitors have proven effective, they also pose chall...

of 2